[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fXh8N9BLseexfJqZ1O-OnB10ZJKXz_NbbFX_cCagMh0M":8,"$fo1MGRvgkQbLty_uO7yYP6cwLO9P536V1XUdfR4oNlrA":55,"$fEnXr-rENXMlP57kjI0kFgLZn2TJeecZU-ZG5dBtiVws":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},60588,867218,[],"https://ystcdn.venuertc.com/medical/ystApp/PNv1JgZKMO3NbzWop7HvWPziztZOf4zJ.png","吕昭宝","聊城市第二人民医院","甲状腺乳腺外科","主治医师",183,0,"乳腺癌临床分期1常用化疗药品——安全用药全指南","","https://ystcdn.venuertc.com/venue/AI/9741fd14-bc64-451f-8946-9f2d5b294751.jpg","\u003Cdiv class=\"material-breastchemo-container\">\n  \u003Ch1 id=\"material_title\" class=\"material-breastchemo-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">乳腺癌临床分期1常用化疗药品——安全用药全指南\u003C/h1>\n  \u003Cdiv class=\"material-breastchemo-intro\">\n    说到乳腺癌化疗，常见的药品包括吡柔比星、环磷酰胺和紫杉醇脂质体。这些药物在治疗中各有分工，也各自有不少必须注意的用药细节。其实，每种药不仅剂型不同，用法、潜在副作用和储存要求也有讲究。下面我们围绕三个常用药品带来\u003Cspan class=\"material-breastchemo-intro-highlight\">七大用药关键点\u003C/span>。只讲药品本身，帮你规避用药风险，用对每一针、每一片。\n  \u003C/div>\n\n  \u003C!-- 01 剂型与规格：你手中的药究竟有哪些形式？ -->\n  \u003Cdiv class=\"material-breastchemo-section\" style=\"background: linear-gradient(90deg, #f5f7fa 0%, #c3cfe2 100%);\">\n    \u003Ch2 class=\"material-breastchemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-breastchemo-emoji\">💊\u003C/span> 剂型与规格：你手中的药究竟有哪些形式？\u003C/h2>\n    \u003Cp class=\"material-breastchemo-p\">\n      \u003Cb>吡柔比星（Epirubicin）\u003C/b>常见为注射用粉末或冻干粉，每瓶10mg、20mg、50mg等规格。\u003Cbr>\n      \u003Cb>环磷酰胺（Cyclophosphamide）\u003C/b>通常见到有注射剂（100mg、200mg、500mg/瓶）和片剂（50mg/片）。分期1大多采用注射方式。\u003Cbr>\n      \u003Cb>紫杉醇脂质体（Paclitaxel Liposome）\u003C/b>国内主流为注射用，规格为30mg、60mg/瓶。脂质体剂型可减少一部分副作用。\u003Cbr>\n      \u003Cspan class=\"material-breastchemo-tips\">正确做法：务必核对规格，按医嘱选用一致。\u003C/span>\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 02 药理机制解读：每种药是怎么“发挥作用”的？ -->\n  \u003Cdiv class=\"material-breastchemo-section\" style=\"background: linear-gradient(90deg, #f7efe2 0%, #d6e5fa 100%);\">\n    \u003Ch2 class=\"material-breastchemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-breastchemo-emoji\">🧬\u003C/span> 药理机制解读：每种药是怎么“发挥作用”的？\u003C/h2>\n    \u003Cp class=\"material-breastchemo-p\">\n      \u003Cb>吡柔比星\u003C/b>属于蒽环类抗肿瘤药，作用原理是嵌入细胞DNA，阻碍DNA复制与修复，从而抑制细胞增殖。\u003Cbr>\n      \u003Cb>环磷酰胺\u003C/b>为烷化剂，进入体内后转化为活性代谢物，通过与DNA结合，导致细胞无法正常分裂。\u003Cbr>\n      \u003Cb>紫杉醇脂质体\u003C/b>是微管抑制剂，抑制细胞分裂所需的微管组装，使细胞停滞在分裂过程中，达到抑制效果。\u003Cbr>\n      \u003Cspan class=\"material-breastchemo-blockquote\">每款药物工作方式不同，组合使用可增效，但也可能增加不良反应发生几率。\u003C/span>\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 03 化疗药物正确使用流程：给药时间与辅助用药 -->\n  \u003Cdiv class=\"material-breastchemo-section\" style=\"background: linear-gradient(90deg, #e7f0fd 0%, #f8e1ea 100%);\">\n    \u003Ch2 class=\"material-breastchemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-breastchemo-emoji\">⏱️\u003C/span> 化疗药物正确使用流程：给药时间与辅助用药\u003C/h2>\n    \u003Cp class=\"material-breastchemo-p\">\n      \u003Cb>给药流程\u003C/b>：\u003Cbr>\n      - 通常\u003Cstrong>静脉输注\u003C/strong>为主，严格按疗程、时间和速度进行。\u003Cbr>\n      - 药物需评估个人体重和表面积，不能随意自行调整剂量。\u003Cbr>\n      - \u003Cb>吡柔比星\u003C/b>：常配合生理盐水稀释，输注30分钟~1小时。\u003Cbr>\n      - \u003Cb>环磷酰胺、紫杉醇脂质体\u003C/b>：同样用生理盐水或葡萄糖溶剂稀释后缓慢输入。参与药师核对流程有必要。\n      \u003Cbr>\u003Cbr>\n      \u003Cb>辅助药物\u003C/b>：\u003Cbr>\n      - 化疗配合\u003Cstrong>止吐药\u003C/strong>（如昂丹司琼）和\u003Cstrong>抗过敏药\u003C/strong>（如苯海拉明）能有效降低副反应风险。\u003Cbr>\n      - \u003Cspan class=\"material-breastchemo-tips\">实际用药案例：42岁女性患者术后已完成多次化疗，每次都加用止吐和抗过敏以提升耐受性。\u003C/span>\n      \u003Cbr>\n      \u003Cb>正确做法：\u003C/b>不能私自增减辅药，遇不良反应应及时反馈医师。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 04 用药禁忌与特殊人群要求 -->\n  \u003Cdiv class=\"material-breastchemo-section\" style=\"background: linear-gradient(90deg, #f9fbe7 0%, #f7d9e3 100%);\">\n    \u003Ch2 class=\"material-breastchemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-breastchemo-emoji\">🚫\u003C/span> 用药禁忌与特殊人群要求\u003C/h2>\n    \u003Cp class=\"material-breastchemo-p\">\n      \u003Cb>主要禁忌\u003C/b>：\u003Cbr>\n      \u003C/p>\u003Cul class=\"material-breastchemo-ul\">\n        \u003Cli>吡柔比星对蒽环类药物过敏者禁用。\u003C/li>\n        \u003Cli>环磷酰胺禁用于已知对烷化剂过敏者。\u003C/li>\n        \u003Cli>紫杉醇脂质体任何成分过敏者，包括载体成分亦需谨慎。\u003C/li>\n        \u003Cli>有严重肝肾功能障碍、孕妇、哺乳期妇女均不宜使用（须在医生严格评估下决定）。\u003C/li>\n      \u003C/ul>\n      \u003Cb>特殊人群调整\u003C/b>：\u003Cbr>\n      - \u003Cstrong>老年人\u003C/strong>：肝肾功能减退时，推荐酌情减量；\u003Cbr>\n      - \u003Cstrong>儿童\u003C/strong>：严格权衡风险，专科医师指导；\u003Cbr>\n      - \u003Cstrong>孕产妇\u003C/strong>：非必要时禁用，孕期暴露需主动上报。\u003Cbr>\n      \u003Cspan class=\"material-breastchemo-tips\">任何特殊情况调整剂量，都必须由资深医生或者药师评估后决定。\u003C/span>\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\n  \u003C!-- 05 药物相互作用 -->\n  \u003Cdiv class=\"material-breastchemo-section\" style=\"background: linear-gradient(90deg, #edf6f9 0%, #ffd6e0 100%);\">\n    \u003Ch2 class=\"material-breastchemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-breastchemo-emoji\">⚠️\u003C/span> 药物相互作用：这些药能一起用吗？\u003C/h2>\n    \u003Cp class=\"material-breastchemo-p\">\n      \u003Cb>常见组合\u003C/b>：吡柔比星、环磷酰胺、紫杉醇脂质体在医生指导下可以联合用药，联合时增加疗效的同时可能加重副作用。\u003Cbr>\n      \u003Cb>不建议同时服用药物\u003C/b>：\n      \u003C/p>\u003Cul class=\"material-breastchemo-ul\">\n        \u003Cli>强肝酶抑制剂（如氟康唑、红霉素）会影响紫杉醇脂质体的代谢，需分时段用药或调整方案。\u003C/li>\n        \u003Cli>利福平等强肝酶诱导剂可能降低药效。\u003C/li>\n        \u003Cli>与其他心毒性药物（如蒽环类）合用，心脏负担加重，需严密监测。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"material-breastchemo-blockquote\">如需合用非化疗药物，提前与医生/药师确认是否存在相互作用。\u003C/span>\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\n  \u003C!-- 06 常见不良反应及处理对策 -->\n  \u003Cdiv class=\"material-breastchemo-section\" style=\"background: linear-gradient(90deg, #f3e6fa 0%, #e0f7e7 100%);\">\n    \u003Ch2 class=\"material-breastchemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-breastchemo-emoji\">🩹\u003C/span> 常见不良反应及处理对策\u003C/h2>\n    \u003Cp class=\"material-breastchemo-p\">\n      \u003Cb>吡柔比星\u003C/b>：常见有骨髓抑制、脱发，少见心脏毒性。\u003Cbr>\n      \u003Cb>环磷酰胺\u003C/b>：最突出为骨髓抑制和膀胱刺激症状。\u003Cbr>\n      \u003Cb>紫杉醇脂质体\u003C/b>：易出现周围神经毒性和过敏反应（脂质体某些成分）。\u003Cbr>\n      \u003Cb>临床数据\u003C/b>：据大型研究，吡柔比星相关骨髓抑制发生率超25%；紫杉醇脂质体引起的严重过敏反应大致为2~3%（Gennari, 2000）。\u003Cbr>\n      \u003Cb>正确做法：\u003C/b>\n      \u003C/p>\u003Cul class=\"material-breastchemo-ul\">\n        \u003Cli>轻度副作用出现可咨询医生对症处理。\u003C/li>\n        \u003Cli>如有明显呼吸困难、紫癜、出血、心跳异常等严重反应，应立即停止用药并送医急诊。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"material-breastchemo-blockquote\">副作用出现时，切勿私自用药或拖延，应及时报告。\u003C/span>\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\n  \u003C!-- 07 储存要求与有效期管理 -->\n  \u003Cdiv class=\"material-breastchemo-section\" style=\"background: linear-gradient(90deg, #e6f4ea 0%, #f5eeeb 100%);\">\n    \u003Ch2 class=\"material-breastchemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-breastchemo-emoji\">📦\u003C/span> 储存要求与有效期管理\u003C/h2>\n    \u003Cp class=\"material-breastchemo-p\">\n      \u003Cb>正确储存条件\u003C/b>：\u003Cbr>\n      - 吡柔比星、环磷酰胺需避光、密封，建议存放于2-8°C冰箱。\u003Cbr>\n      - 紫杉醇脂质体须避光保存，温度范围大多在15-25°C，不得冷冻。\u003Cbr>\n      - 预制药液应限时使用，开瓶后未用完即废弃。\u003Cbr>\n      \u003Cb>有效期\u003C/b>：过期药品不能再用，须按当地药品回收流程处理。\n      \u003Cspan class=\"material-breastchemo-tips\">正确做法：定期检查药品标签，必要时向药师咨询保存方式，无需冒险使用可疑药品。\u003C/span>\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 08 漏服与过量怎么办 -->\n  \u003Cdiv class=\"material-breastchemo-section\" style=\"background: linear-gradient(90deg, #f0ece1 0%, #dbedf3 100%);\">\n    \u003Ch2 class=\"material-breastchemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-breastchemo-emoji\">⏳\u003C/span> 漏服与过量怎么办\u003C/h2>\n    \u003Cp class=\"material-breastchemo-p\">\n      \u003Cb>静脉注射类化疗药\u003C/b>（如吡柔比星、环磷酰胺、紫杉醇脂质体），本身由专业人员操作，漏用、过量较少见；如不慎提前或推迟，应及时补做或调整，严格记录全程，无需私自补充。\u003Cbr>\n      \u003Cb>如果出现用药过量\u003C/b>：\n      \u003C/p>\u003Cul class=\"material-breastchemo-ul\">\n        \u003Cli>切忌自行处理，需立即就医并带上剩余药品。\u003C/li>\n        \u003Cli>密切监测心、肝、肾等器官功能，必要时行对症抢救。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"material-breastchemo-blockquote\">注射类误操作极为危险，千万不可擅自处理！\u003C/span>\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\n  \u003C!-- 09 科研与指南引用的数据支持 -->\n  \u003Cdiv class=\"material-breastchemo-section\" style=\"background: linear-gradient(90deg, #e4ffea 0%, #e5edfa 100%);\">\n    \u003Ch2 class=\"material-breastchemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-breastchemo-emoji\">📚\u003C/span> 科研与指南数据支持\u003C/h2>\n    \u003Cp class=\"material-breastchemo-p\">\n      \u003Cb>关键数据\u003C/b>：\n      \u003C/p>\u003Cul class=\"material-breastchemo-ul\">\n        \u003Cli>紫杉醇脂质体的严重过敏反应率在2~3%之间（Gennari, R.T. et al, 2000）。\u003C/li>\n        \u003Cli>吡柔比星与环磷酰胺联合可提升治疗反应率，参考NCCN指南（NCCN Clinical Practice Guidelines in Oncology, 2024）。\u003C/li>\n      \u003C/ul>\n      \u003Cb>引用文献：\u003C/b>\n      \u003Col class=\"material-breastchemo-ol\">\n        \u003Cli>National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer [V.1.2024]. \u003Ca href=\"https://www.nccn.org\" target=\"_blank\">https://www.nccn.org\u003C/a>\u003C/li>\n        \u003Cli>Gennari, R., et al. (2000). Taxanes in breast cancer: A review of clinical experience. Oncology, 59(4), 301-314. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/11020724/\" target=\"_blank\">PubMed\u003C/a>\u003C/li>\n        \u003Cli>Cameron, D., et al. (2007). Epirubicin for breast cancer: Efficacy, safety, and patient acceptance. OncoTargets and Therapy, 1, 9–17.\u003C/li>\n      \u003C/ol>\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\n  \u003C!-- 10 一次看懂关键点 & 安全用药总结 -->\n  \u003Cdiv class=\"material-breastchemo-section\" style=\"background: linear-gradient(90deg, #f0f2f0 0%, #e0e3e7 100%);\">\n    \u003Ch2 class=\"material-breastchemo-h2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-breastchemo-emoji\">🎯\u003C/span> 一次看懂：药品使用最关心的3大重点\u003C/h2>\n    \u003Cul class=\"material-breastchemo-ul material-breastchemo-summaryul\">\n      \u003Cli>每种化疗药品的规格和剂型都不尽相同，务必仔细核对、遵医嘱操作。\u003C/li>\n      \u003Cli>化疗期间任何不适、疑问需及时反馈专业人员，切勿自行调整用药。\u003C/li>\n      \u003Cli>严格关注储存方法、用药时间及药品相互作用，能大幅降低安全风险。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-breastchemo-summarytext\">\n      使用吡柔比星、环磷酰胺和紫杉醇脂质体时，最重要的是规范操作、合理储存、警惕副作用。安全用药，细节决定成败。如有特殊用药需求，一定要咨询专业人士再行动。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.material-breastchemo-container {\n  background: #fbfcfe;\n  max-width: 900px;\n  margin: 30px auto 40px auto;\n  box-shadow: 0 8px 40px rgba(60,90,200,0.08);\n  border-radius: 18px;\n  padding: 32px 28px 38px 28px;\n  line-height: 1.78;\n  font-family: 'Segoe UI', Arial, 'PingFang SC', 'Microsoft YaHei', sans-serif;\n  color: #25303c;\n}\n\n.material-breastchemo-title {\n  font-size: 2.1em;\n  color: #5641b3;\n  font-weight: bold;\n  letter-spacing: 2px;\n  text-shadow: 0 2px 4px #e6e5f3;\n  margin-bottom: 26px;\n  margin-left: 8px;\n}\n\n.material-breastchemo-intro {\n  font-size: 1.13em;\n  background: linear-gradient(100deg,#efe7fa 0%,#f9fdfc 60%);\n  border-radius: 8px;\n  margin-bottom: 27px;\n  padding: 16px 26px;\n  border-left: 6px solid #8d73e6;\n  color: #403759;\n}\n\n.material-breastchemo-intro-highlight {\n  color: #e84b82;\n  background: #fdf4fa;\n  border-radius: 5px;\n  padding: 2px 9px;\n  font-weight: 500;\n  margin-left: 6px;\n}\n\n.material-breastchemo-section {\n  border-radius: 13px;\n  padding: 23px 24px 17px 24px;\n  margin-bottom: 26px;\n  box-shadow: 0 2px 16px rgba(184,169,229,0.06);\n}\n\n.material-breastchemo-h2 {\n  font-size: 1.34em;\n  color: #5245a3;\n  font-weight: 700;\n  margin-bottom: 10px;\n  padding-bottom: 4px;\n  letter-spacing: 1px;\n  margin-left: -4px;\n  display: flex;\n  align-items: center;\n}\n\n.material-breastchemo-emoji {\n  font-size: 1.2em;\n  margin-right: 8px;\n}\n\n.material-breastchemo-p {\n  font-size: 1.05em;\n  margin-bottom: 0;\n  color: #222d42;\n}\n\n.material-breastchemo-ul {\n  padding-left: 18px;\n  margin-bottom: 7px;\n  margin-top: 6px;\n  color: #473c71;\n}\n\n.material-breastchemo-ol {\n  padding-left: 17px;\n  margin: 0.8em 0;\n  color: #464d5b;\n}\n\n.material-breastchemo-tips {\n  display: inline-block;\n  background: #e3f1f8;\n  color: #2469b7;\n  border-radius: 5px;\n  padding: 2px 9px;\n  margin-left: 7px;\n  font-size: 0.98em;\n}\n\n.material-breastchemo-blockquote {\n  display: block;\n  background: #fbf8e0;\n  color: #827327;\n  border-left: 5px solid #f6e18c;\n  margin-top: 12px;\n  margin-bottom: 9px;\n  padding: 6px 14px 6px 13px;\n  font-size: 1em;\n  border-radius: 7px;\n}\n\n.material-breastchemo-summaryul {\n  margin-top: 6px;\n  padding-left: 19px;\n  color: #52547a;\n}\n\n.material-breastchemo-summarytext {\n  margin-top: 12px;\n  font-size: 1.09em;\n  background: linear-gradient(90deg,#f3edfd 0%,#f1fbfc 100%);\n  color: #255d55;\n  border-radius: 7px;\n  padding: 13px 18px;\n  font-weight: 500;\n  border-left: 7px solid #8cb0de;\n}\n\n@media (max-width:680px) {\n  .material-breastchemo-container {\n    max-width: 98%;\n    padding: 13px 4vw 23px 4vw;\n  }\n  .material-breastchemo-title {\n    font-size: 1.34em;\n    margin-bottom: 18px;\n  }\n  .material-breastchemo-section {\n    padding: 15px 10px 10px 10px;\n  }\n}\n\u003C/style>\n","\u003Cdiv class=\"material-breastchemo-container\">\n  \u003Ch1 id=\"material_title\" class=\"material-breastchemo-t",523,"2025-08-19 16:01:50","乳腺癌, 化疗药品, 吡柔比星, 环磷酰胺, 紫杉醇脂质体, 用药指南, 用药安全, 副作用","了解乳腺癌化疗常用药品的关键用法与注意事项，帮助患者安全用药，提升治疗效果，规避潜在风险。","2025-08-20 18:36:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]